131I治疗术后分化型甲状腺癌的疗效及其影响因素
Clinical Curative Effect of Differentiated Thyroid Carcinoma Treated by Using Large 131I and 1st Influencing Factors
-
摘要:
目的 分析大剂量131I治疗术后分化型甲状腺癌(DTC)患者疗效及其影响因素.方法 对216例DTC患者术后接受131I治疗的临床资料进行回顾性分析.对每次服131I后第4天131I全身显像进行对比观察作为判断疗效的依据,根据患者病理类型、转移部位、服131I次数分别观察其总体疗效.结果 大剂量131I治疗术后DTC患者总有效率86.57%,对于颈部淋巴结转移的疗效明显优于纵隔转移、肺转移及骨转移,无明显不良反应,安全可靠.结论 术后联合大剂量131I治疗对于分化型甲状腺癌是一种有效而又安全的方法,癌灶转移部位对131I治疗的疗效有一定的影响.
Abstract:Objective To retrospectively analyze the curative effect of 131I therapy for treating post-operative differentiated thyroid carcinoma( DTC) and the influencing factors. Methods Two hundred and sixteen post-operative DTC patients who had received 131I therapy were involved in this retrospective study. The efficacy was assessed by 131I whole body scan in four days after the therapy every time. Besides,the overall curative effect was observed according to patients' pathological type,location of metastasis and frequency of 131I therapy respectively.Results After high dose 131I treatment, the total effective rate in patients with was 86.57%. The curative effect on cervical lymph node metastasis of DTC was significantly better than that of lung metastasis and bone metastasis.Meanwhile, no obvious side effects were observed during the study.Conclusions Large dose of 131I therapy for DTC metastasis is safe and effective. The location of tumor metastasis may influence the curative effect.
-
Key words:
- Differentiated thyroid cancer /
- 131I odine /
- Therapeutics
-
[1] [1]SAMPSON E,BRIERLEY J D,LE L W,et al.Clinical management and outcome of papillary and follicular(differentiated)thyroid cancer presenting with distant metastasis at diagnosis[J].Cancer,2007,110(7):1451-1456. [2]李磊,冀叶,孙瑞梅,等.2003年至2011年云南省肿瘤医院头颈部恶性肿瘤病谱分析[J].昆明医科大学学报2012,33(9):66-69. [3] [3]LEE J,SOH EY.Differentiated thyroid carcinoma presentingwith distant metastasis at initial diagnosis clinical outcomes and prognostic factors[J].Ann Surg,2010,251(1):114-119. [4] [4]HOGAN A R,ZHUGE Y,PEREZ E A,et al.Pediatric thyroid carcinoma:Incidence and outcomes in 1753 patients[J].J Surg Res,2009,156(1):167-172. [5] [5]MALLICK U,HARMER C,YAP B,et al.Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer[J].N En-gl J Med,2012,366(18):1674-1685. [6] [6]SCHLUMBERGER M,CATARGI B,BORGET I,et al.Strategies of radioiodine ablation in patients with low-risk thyroid cancer[J].N Engl J Med,2012,366(18):1663-1673. [7]张超杰,范培芝,张志功,等.碘131治疗分化型甲状腺癌误区的认识与思考[J].医学与哲学,2012,33(20):17-20. [8] [8]IBRAHIMPASIC T,NIXON I J,PALMER F L,et al.Undetectable thyroglobulin after total thyroidectomy in patients with low-and intermediate-risk papillary thyroid cancer is there a need for radioactive iodine therapy[J].Surgery,2012,152(6):1096-1105. [9]李镜发,邹德环,佘立群,等.甲状腺癌术后大剂量131I治疗疗效分析[J].中华实用诊断与治疗杂志,2013,27(2):129-133. [10]李志红.促甲状腺激素抑制疗法在分化型甲状腺癌治疗中的作用[J].实用临床医药杂志,2013,17(9):107-108. [11] [11]MIHAILOVIC J,STEFANOVIC L,STANKOVIC R.Influence of initialtreatment on the survival and recurrence in patients with differentiated thyroid microcarcinoma[J].Clin Nucl Med,2013,38(5):332-338. [12] [12]BISCHOFF L A,CURRY J,AHMED I,et al.Is above age45 appropriate for upstaging well-differentiated papillary thyroid cancer[J].Endocr Pract,2013,19(6):995-997. [13] [13]ITO Y,KUDO T,KIHARA M,et al.Prognosis of low-risk papillary thyroid carcinoma patients:Its relationship with the size of primary tumors[J].Endocr J,2012,59(2):119-125. [14]赵劼,孙辉,温强,等.分化型甲状腺癌术后131I清除剩余甲状腺及治疗甲癌转移灶的临床作用[J].吉林医学.2006,27(2):117-118. [15]关海霞,陆汉魁.分化型甲状腺癌的131I消融治疗[J].外科理论与实践.2012,17(01):15-16. [16]张学东,李保军,赵现斌,等.甲状腺癌切除术后131I清除甲状腺残余组织疗效的相关因素分析[J].中国医药导报.2012,9(25):50-54. [17]唐彩华,贾晓娟,许泽清.73例分化型甲状腺癌术后131I治疗随访结果分析[J].肿瘤学杂志,2014,20(01):72-74. [18]黄勇,谢建平,李素平,等.131I甲状腺癌疗效的影响因素[J].川北医学院学报,2011,26(3):274-277. [19] [19]CIAPPUCCINI R,HARDOUIN J,HEUTTE N,et al.Stimulated thyroglobulin level at ablation in differentiated thyroid cancer:the impact of treatment preparation modalities and tumor burden[J].Eur J Endocrinol,2014,171(2):247-252. [20]屈伟,丁石梅,王社教,等.术后分化型甲状腺癌131I清甲治疗疗效及影响因素分析[J].现代肿瘤医学,2013,21(10):2209-2211. [20]余永利,罗全勇,陈立波,等.分化型甲状腺癌术后131I治疗对复发的影响[J].中华核医学杂志,2004,24(04):25-27. [22]黄治文,肖欢,李诗运,等.131I治疗分化型甲状腺癌术后转移灶的疗效分析[J].海南医学,2011,22(10):67-68. [23]陆汉魁,余永利,罗全勇,等.131I治疗分化型甲状腺癌合并远处转移的疗效及影响因素[J].上海第二医科大学学报,2005,25(12):1263-1266. [24] [24]TENG W P,LIU Y F,GAO M,et al.Chinese management guidelines for patients with thyroid nodules and differentiated thyroid cancer[J].Chin J Endocrinol Metab,2012,28(10):779-797. [25] [25]NIXON I J,WHITCHER M,PALMER F L,et al.The impact of distant metastases at presentation on prognosis in patients withdifferentiated carcinoma of the thyroid gland[J].Thyroid,2012,22(9):884-889.
计量
- 文章访问数: 1818
- HTML全文浏览量: 626
- PDF下载量: 96
- 被引次数: 0